The Bob Harrington Show

Volunteering at a VA hospital was the first step in biostatistician Frank Harrell's illustrious career in cardiovascular research.

Despite the vastness of available data, don't forget the basics, warns biostatistician Frank Harrell in this conversation with Bob Harrington.

Drs Harrington and Yeh discuss the pros, cons, and cautions of using Twitter in the cardiovascular community.

Drs Harrington and Joynt Maddox discuss the move from volume-based to performance-based payment models and how to develop evidence-based quality metrics that make clinical sense.

Drs Harrington and Gibson discuss burning issues in medicine, including artificial intelligence, social media, wearable tech, and the new hypertension guidelines.

Trials on PCSK9 inhibitors, antiplatelets, anticoagulants, and even catheter ablation of atrial fibrillation are among Drs Harrington and Gibson's picks for what to look for in 2018.

A recent viewpoint by Dr Bhatt against public reporting of PCI outcomes garnered a lot of support in the cardiology community and beyond. Dr Harrington asks how it can be done better.

In this annual tradition, Drs Harrington and Gibson discuss their picks for the top cardiology trials of the year, covering PCSK9 inhibitors, anti-inflammatory and anthithrombotic drugs, and PCI.

Drs Harrington and Kesselheim discuss the varied reasons why prescription drugs are so pricey and whether policies can interrupt this alarming trend.

Dr Califf talks about his new role at Verily and how data mining and data sharing could reduce disparities in care and improve patient outcomes.